Stabilized liquid anti-RSV antibody formulations

A method for preventing a symptom of a RSV infection, comprising administering to a human subject an aqueous palivizumab formulation comprising, in an aqueous carrier:

• (a) at least 75 mg/ml of palivizumab or an antigen-binding fragment thereof;
• (b) histidine at a concentration of 23 mM to 27 mM;
• and (c) glycine at a concentration of less than 2 mM, wherein said formulation has a pH of between about 5.5 to 6.5, and wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 2° C. to 8° C. for at least 15 months as determined by HPSEC.

A method for preventing a symptom of a RSV infection, comprising administering to a human subject an aqueous palivizumab formulation comprising, in an aqueous carrier:

• (a) at least 95 mg/ml of palivizumab or an antigen-binding fragment thereof;
• (b) histidine at a concentration of about 25 mM;
• and (c) glycine at a concentration of 1.6 mM, wherein said formulation has a pH of between about 5.5 to 6.5, and wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 2° C. to 8° C. for at least 15 months as determined by HPSEC.

A method for preventing a symptom of a RSV infection, comprising administering to a human subject an aqueous palivizumab formulation comprising, in an aqueous carrier:

• (a) at least 95 mg/ml of palivizumab or an antigen-binding fragment thereof;
• (b) histidine at a concentration of about 25 mM;
• and (c) glycine at a concentration of 1.6 mM, wherein said formulation has a pH of between about 5.8 to 6.2 and does not contain mannitol, and wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 2° C. to 8° C. for at least 15 months as determined by HPSEC.

A method for preventing serious lower respiratory tract disease caused by RSV in pediatric patients, comprising administering to a pediatric patient an aqueous palivizumab formulation comprising, in an aqueous carrier:

• (a) 103±3 mg/ml of palivizumab or an antigen-binding fragment thereof;
• (b) histidine at a concentration of 25 mM;
• and (c) glycine at a concentration of 1.6 mM, wherein said formulation has a pH of 6.0 does not contain mannitol, and wherein said palivizumab or palivizumab antigen-binding fragment in the formulation is stable at 2° C. to 8° C. for at least 15 months as determined by HPSEC.